Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gastric Cancer

  Free Subscription

Articles published in
BMC Cancer
    March 2024
  1. LIU D, Quan H, Ma M, Zhou H, et al
    Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.
    BMC Cancer. 2024;24:344.
    >> Share

  2. CHEN Y, Chen X, Lin Y, Zhang S, et al
    Correction: Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:314.
    >> Share

  3. WANG J, Shao M, Hu H, Xiao W, et al
    Convolutional neural network applied to preoperative venous-phase CT images predicts risk category in patients with gastric gastrointestinal stromal tumors.
    BMC Cancer. 2024;24:280.
    >> Share

    February 2024
  4. ZHANG J, Wang L, Zhang S, Cao R, et al
    Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
    BMC Cancer. 2024;24:266.
    >> Share

  5. CHEN Y, Chen X, Lin Y, Zhang S, et al
    Oncological risk of proximal gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:255.
    >> Share

  6. LIM SH, Lee KW, Kim JJ, Im HS, et al
    Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
    BMC Cancer. 2024;24:252.
    >> Share

  7. LI ZZ, Yan XL, Zhang Z, Chen JL, et al
    Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.
    BMC Cancer. 2024;24:253.
    >> Share

  8. DE MORAES FCA, Pasqualotto E, Chavez MP, Ferreira ROM, et al
    Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    BMC Cancer. 2024;24:240.
    >> Share

  9. SUI H, Lou A, Li Z, Yang J, et al
    Retraction Note: Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145.
    BMC Cancer. 2024;24:241.
    >> Share

  10. ZHENG HL, Wang FH, Zhang LK, Li P, et al
    Trajectories of neutrophil-to-lymphocyte ratios during neoadjuvant chemotherapy correlate with short- and long-term outcomes in gastric cancer: a group-based trajectory analysis.
    BMC Cancer. 2024;24:226.
    >> Share

  11. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
    Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
    BMC Cancer. 2024;24:191.
    >> Share

    January 2024
  12. HONG Z, Wen P, Wang K, Wei X, et al
    The macrophage-associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis.
    BMC Cancer. 2024;24:141.
    >> Share

  13. WEI L, Wu X, Wang L, Chen L, et al
    Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells.
    BMC Cancer. 2024;24:15.
    >> Share

  14. QU T, Zhang S, Yang S, Li S, et al
    Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients.
    BMC Cancer. 2024;24:27.
    >> Share

    December 2023
  15. ZHU G, Cai H, Xiao Q, Zeng S, et al
    GRB7 plays a promoting role in the progression of gastric cancer.
    BMC Cancer. 2023;23:1262.
    >> Share

  16. CHE J, Zhao Y, Gu B, Li S, et al
    Untargeted serum metabolomics reveals potential biomarkers and metabolic pathways associated with the progression of gastroesophageal cancer.
    BMC Cancer. 2023;23:1238.
    >> Share

  17. NIE C, Xu W, Guo Y, Gao X, et al
    Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    BMC Cancer. 2023;23:1239.
    >> Share

  18. GAO J, Lan J, Liao H, Yang F, et al
    Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.
    BMC Cancer. 2023;23:1205.
    >> Share

  19. BOBRZYNSKI L, Sedlak K, Rawicz-Pruszynski K, Kolodziejczyk P, et al
    Evaluation of optimum classification measures used to define textbook outcome among patients undergoing curative-intent resection of gastric cancer.
    BMC Cancer. 2023;23:1199.
    >> Share

  20. JEON CH, Park KB, Lee H, Kim DJ, et al
    Refining gastric cancer staging: examining the interplay between number and anatomical location of metastatic lymph nodes - a retrospective multi-institutional study.
    BMC Cancer. 2023;23:1192.
    >> Share

    November 2023
  21. WEI C, He Y, Luo M, Chen G, et al
    The role of computed tomography features in assessing response to neoadjuvant chemotherapy in locally advanced gastric cancer.
    BMC Cancer. 2023;23:1157.
    >> Share

  22. ZHENG H, Yin X, Pan T, Tao X, et al
    Effect of different surgical approaches on the survival and safety of Siewert type II esophagogastric junction adenocarcinoma: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1130.
    >> Share

  23. CHEN YY, Li BP, Wang JF, Wang Y, et al
    Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer.
    BMC Cancer. 2023;23:1122.
    >> Share

  24. LIU X, Ren J, Zhou R, Wen Z, et al
    Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database.
    BMC Cancer. 2023;23:1106.
    >> Share

  25. YANG Y, Li Y, Chen Z
    Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.
    BMC Cancer. 2023;23:1095.
    >> Share

  26. TAKASHIMA Y, Komatsu S, Nishibeppu K, Ohashi T, et al
    A shorter distal resection margin is a surrogate marker of nodal metastasis and poor prognosis in distal gastrectomy for advanced gastric cancer.
    BMC Cancer. 2023;23:1075.
    >> Share

    October 2023
  27. LUKSTA M, Bausys A, Bickaite K, Rackauskas R, et al
    Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study.
    BMC Cancer. 2023;23:1032.
    >> Share

  28. QYI YZ, Aung HH, Aye SN, Tung WS, et al
    Toll-like receptor 9 (-1237 T/C, -1486 T/C) and the risk of gastric cancer: a meta-analysis of genetic association studies.
    BMC Cancer. 2023;23:1027.
    >> Share

  29. SUN C, Niu P, Zhang X, Zhao L, et al
    Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study.
    BMC Cancer. 2023;23:996.
    >> Share

  30. MAKUUCHI R, Terashima M, Terada M, Mizusawa J, et al
    Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol.
    BMC Cancer. 2023;23:987.
    >> Share

  31. BEIHAGHI M, Sahebi R, Beihaghi MR, Nessiani RK, et al
    Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer.
    BMC Cancer. 2023;23:985.
    >> Share

  32. NARA K, Yamamoto T, Yamashita H, Yagi K, et al
    Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab the
    BMC Cancer. 2023;23:979.
    >> Share

  33. WU D, Lu J, Xue Z, Zhong Q, et al
    Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis.
    BMC Cancer. 2023;23:964.
    >> Share

  34. WANG Y, Guo Z, Tian Y, Cong L, et al
    MAPK1 promotes the metastasis and invasion of gastric cancer as a bidirectional transcription factor.
    BMC Cancer. 2023;23:959.
    >> Share

  35. XIANG L, Jin S, Yu Y, Wang D, et al
    Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:933.
    >> Share

  36. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    >> Share

  37. XIA B, Gu X, Xu T, Yan M, et al
    Exosomes-mediated transfer of LINC00691 regulates the formation of CAFs and promotes the progression of gastric cancer.
    BMC Cancer. 2023;23:928.
    >> Share

    September 2023
  38. KIM Y, Bae YJ, Kim JH, Kim H, et al
    Wnt/beta-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells.
    BMC Cancer. 2023;23:922.
    >> Share

  39. SUN Y, Chen C, Hou L, Zhao E, et al
    Short-term and long-term outcomes of patients with gastric cancer during versus before the COVID-19 pandemic: cohort study using propensity score matching method.
    BMC Cancer. 2023;23:913.
    >> Share

  40. WU J, Tian S, Xu J, Cheng N, et al
    Association of high-risk comorbidity with overall survival among patients with gastric cancer and its sex-specific differences in China: a retrospective observational cohort study.
    BMC Cancer. 2023;23:916.
    >> Share

  41. SAHIN MEH, Akbas F, Yardimci AH, Sahin E, et al
    The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer.
    BMC Cancer. 2023;23:911.
    >> Share

  42. MA X, Pierce E, Anand H, Aviles N, et al
    Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer.
    BMC Cancer. 2023;23:910.
    >> Share

  43. ZHAO L, Zhang F, Jiao F, Zhou X, et al
    The minimum number of examined lymph nodes was 24 for optimal survival of pathological T2-4 gastric cancer: a multi-center, hospital-based study covering 20 years of data.
    BMC Cancer. 2023;23:892.
    >> Share

    August 2023
  44. HIGUCHI S, Suehiro Y, Izuhara L, Yoshina S, et al
    BCL7B, a SWI/SNF complex subunit, orchestrates cancer immunity and stemness.
    BMC Cancer. 2023;23:811.
    >> Share

  45. DI Y, Ding L, Gao L, Huang H, et al
    Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:782.
    >> Share

  46. SHIH YH, Lin HC, Liao PW, Chou CW, et al
    The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study.
    BMC Cancer. 2023;23:770.
    >> Share

  47. HAN Y, Wu J, Ji R, Tan H, et al
    Preoperative sarcopenia combined with prognostic nutritional index predicts long-term prognosis of radical gastrectomy with advanced gastric cancer: a comprehensive analysis of two-center study.
    BMC Cancer. 2023;23:751.
    >> Share

  48. TAKAHASHI N, Hara H, Nagashima K, Hirata K, et al
    Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
    BMC Cancer. 2023;23:726.
    >> Share

    July 2023
  49. YOON C, Lu J, Jun Y, Suh YS, et al
    KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis.
    BMC Cancer. 2023;23:690.
    >> Share

  50. YANAGIMOTO Y, Imamura H, Adachi S, Odagiri K, et al
    The effect of specimen processing time on HER2 expression in gastric cancer and esophagogastric junction cancer: a single-center retrospective observational study.
    BMC Cancer. 2023;23:645.
    >> Share

    June 2023
  51. HAN Y, Wang X, Xu M, Teng Z, et al
    Aspartoacylase promotes the process of tumour development and is associated with immune infiltrates in gastric cancer.
    BMC Cancer. 2023;23:604.
    >> Share

  52. JEON CH, Park KB, Kim S, Seo HS, et al
    Predictive model for long-term weight recovery after gastrectomy for gastric cancer: an introduction to a web calculator.
    BMC Cancer. 2023;23:580.
    >> Share

  53. LORENZEN S, Schwarz A, Pauligk C, Goekkurt E, et al
    Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/I
    BMC Cancer. 2023;23:561.
    >> Share

  54. SHEN X, Liu H, Zhou H, Cheng Z, et al
    Galectin-1 promotes gastric cancer peritoneal metastasis through peritoneal fibrosis.
    BMC Cancer. 2023;23:559.
    >> Share

  55. TIAN Y, Pang Y, Yang PG, Guo HH, et al
    Clinical implications of micro lymph node metastasis for patients with gastric cancer.
    BMC Cancer. 2023;23:536.
    >> Share

  56. E Y, Yu Q, Sun T, Xue H, et al
    The relationship between pepsinogen C and gastric carcinogenesis: a transgene and population study.
    BMC Cancer. 2023;23:520.
    >> Share

  57. LI Y, Wu G, Liu J, Zhang Y, et al
    Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:523.
    >> Share

  58. DU Y, Yu X, Chang ET, Yin L, et al
    EBV antibody and gastric cancer risk: a population-based nested case-control study in southern China.
    BMC Cancer. 2023;23:521.
    >> Share

  59. ZHAO Z, Zhu Y
    FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.
    BMC Cancer. 2023;23:507.
    >> Share

    May 2023
  60. LEONG E, Ong SK, Si-Ramlee KA, Naing L, et al
    Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020.
    BMC Cancer. 2023;23:466.
    >> Share

  61. XU D, Liu X, Ke S, Guo Y, et al
    CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.
    BMC Cancer. 2023;23:464.
    >> Share

  62. ZHANG H, Wang H, Ye L, Bao S, et al
    Comprehensive transcriptomic analyses identify KDM genes-related subtypes with different TME infiltrates in gastric cancer.
    BMC Cancer. 2023;23:454.
    >> Share

  63. HAMADA T, Higashi M, Yokoyama S, Akahane T, et al
    MALAT1 functions as a transcriptional promoter of MALAT1::GLI1 fusion for truncated GLI1 protein expression in cancer.
    BMC Cancer. 2023;23:424.
    >> Share

  64. YANG H, Wang JB, Wang XK, Fan JH, et al
    Association between type of drinking water and upper gastrointestinal cancer incidence in the Linxian General Population.
    BMC Cancer. 2023;23:397.
    >> Share

    April 2023
  65. LIU Y, Shen S, Yan Z, Yan L, et al
    Expression characteristics and their functional role of IGFBP gene family in pan-cancer.
    BMC Cancer. 2023;23:371.
    >> Share

  66. CUI Y, Yu Y, Zheng S, Ying J, et al
    Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).
    BMC Cancer. 2023;23:308.
    >> Share

    March 2023
  67. WANG H, Cui H, Yang X, Peng L, et al
    TUBA1C: a new potential target of LncRNA EGFR-AS1 promotes gastric cancer progression.
    BMC Cancer. 2023;23:258.
    >> Share

  68. YANG J, Li J, Deng Q, Chen Z, et al
    Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer.
    BMC Cancer. 2023;23:246.
    >> Share

  69. KAMIYA H, Komatsu S, Nishibeppu K, Ohashi T, et al
    Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction.
    BMC Cancer. 2023;23:218.
    >> Share

  70. ZHANG L, Wang W, Ge S, Li H, et al
    Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
    BMC Cancer. 2023;23:211.
    >> Share

    February 2023
  71. XIAO H, Bertwistle D, Khela K, Middleton-Dalby C, et al
    Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
    BMC Cancer. 2023;23:186.
    >> Share

  72. LAM LL, Pavlakis N, Shitara K, Sjoquist KM, et al
    INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
    BMC Cancer. 2023;23:180.
    >> Share

  73. STIEFEL R, Lehmann K, Winder T, Siebenhuner AR, et al
    What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
    BMC Cancer. 2023;23:148.
    >> Share

  74. HUO G, Liu W, Chen P
    Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
    BMC Cancer. 2023;23:143.
    >> Share

    January 2023
  75. ZHOU Z, Guo S, Lai S, Wang T, et al
    Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer.
    BMC Cancer. 2023;23:108.
    >> Share

  76. DONG C, Luan F, Tian W, Duan K, et al
    Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis.
    BMC Cancer. 2023;23:76.
    >> Share

  77. YANG J, Su H, Chen T, Chen X, et al
    Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers.
    BMC Cancer. 2023;23:64.
    >> Share

  78. YANG X, Wang A, Li J, Zhou K, et al
    Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).
    BMC Cancer. 2023;23:53.
    >> Share

  79. LIANG XW, Xiao WS, Lei H, Huag QC, et al
    Risk model and factors for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer-a two-center cohort study.
    BMC Cancer. 2023;23:41.
    >> Share

  80. LI L, Huang X, Zhang S, Zhan Z, et al
    Rapid and label-free detection of gastrointestinal stromal tumor via a combination of two-photon microscopy and imaging analysis.
    BMC Cancer. 2023;23:38.
    >> Share

  81. ZHANG R, Hu C, Zhang J, Zhang Y, et al
    Prognostic significance of inflammatory and nutritional markers in perioperative period for patients with advanced gastric cancer.
    BMC Cancer. 2023;23:5.
    >> Share

    December 2022
  82. DAY F, Sridharan S, Lynam J, Gedye C, et al
    Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trial
    BMC Cancer. 2022;22:1324.
    >> Share

  83. WANG Y, Lei X, Shan F, Li S, et al
    Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study.
    BMC Cancer. 2022;22:1306.
    >> Share

  84. TERASHIMA T, Konishi H, Sato Y, Igarashi M, et al
    Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: a nationwide study.
    BMC Cancer. 2022;22:1303.
    >> Share

    November 2022
  85. DU Y, Chen Y, Wu T, Fan X, et al
    Correction: miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer.
    BMC Cancer. 2022;22:1234.
    >> Share

  86. ZHANG C, Wu B, Yang H, Yao Z, et al
    The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
    BMC Cancer. 2022;22:1223.
    >> Share

  87. SUN H, Wang X, Zhang X, Wang X, et al
    Multiplexed immunofluorescence analysis of CAF-markers, EZH2 and FOXM1 in gastric tissue: associations with clinicopathological parameters and clinical outcomes.
    BMC Cancer. 2022;22:1188.
    >> Share

  88. YANG T, Xu R, You J, Li F, et al
    Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.
    BMC Cancer. 2022;22:1168.
    >> Share

  89. XU M, Qiao X, Li L, Liu S, et al
    Application of preoperative CT texture analysis in papillary gastric adenocarcinoma.
    BMC Cancer. 2022;22:1161.
    >> Share

  90. WEI C, Li C, Chen X, Chen G, et al
    Development and verification of a nomogram for predicting the prognosis of resectable gastric cancer with outlet obstruction.
    BMC Cancer. 2022;22:1154.
    >> Share

  91. ZHANG X, Xu S, Wang J, Lv Y, et al
    Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
    BMC Cancer. 2022;22:1136.
    >> Share

  92. KATTAN J, Karak FE, Farhat F, Gerges DA, et al
    Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients.
    BMC Cancer. 2022;22:1114.
    >> Share

    October 2022
  93. LIANG J, Dai W, Li Z, Liang X, et al
    Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI.
    BMC Cancer. 2022;22:1033.
    >> Share

  94. LAI MY, Kang SY, Sun YT, Quan TT, et al
    Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer.
    BMC Cancer. 2022;22:1031.
    >> Share

    September 2022
  95. DONG C, Sun J, Ma S, Zhang G, et al
    Retraction Note: K-ras-ERK1/2 down-regulates H2A.X(Y142ph) through WSTF to promote the progress of gastric cancer.
    BMC Cancer. 2022;22:959.
    >> Share

  96. LI Y, Zhao J, Chen R, Chen S, et al
    Integration of clinical and transcriptomics reveals programming of the lipid metabolism in gastric cancer.
    BMC Cancer. 2022;22:955.
    >> Share

  97. KIM TH, Ahn MS, Choi YW, Kang SY, et al
    Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study.
    BMC Cancer. 2022;22:948.
    >> Share

    August 2022
  98. LIN Z, Zeng H, Xiong W, Li J, et al
    Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?
    BMC Cancer. 2022;22:927.
    >> Share

  99. XU H, Zhang H, Guo W, Zhong X, et al
    Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
    BMC Cancer. 2022;22:923.
    >> Share

  100. CHE H, Xiong Q, Ma J, Chen S, et al
    Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
    BMC Cancer. 2022;22:904.
    >> Share

  101. NGUYEN MT, Huynh NNY, Nguyen DD, Ta NH, et al
    Vitamin D intake and gastric cancer in Viet Nam: a case-control study.
    BMC Cancer. 2022;22:838.
    >> Share

    July 2022
  102. ENDO S, Terazawa T, Goto M, Tanaka R, et al
    Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    BMC Cancer. 2022;22:811.
    >> Share

  103. LE HX, Truong DTT, Tran LB, Le PH, et al
    A prospective cohort study on the association between waterpipe tobacco smoking and gastric cancer mortality in Northern Vietnam.
    BMC Cancer. 2022;22:803.
    >> Share

  104. NAM S, Lee Y, Kim JH
    RHOA protein expression correlates with clinical features in gastric cancer: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:798.
    >> Share

  105. YAMAGUCHI T, Kawakami H, Sakai D, Kurokawa Y, et al
    Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S - 1 therapy.
    BMC Cancer. 2022;22:773.
    >> Share

  106. HE XJ, Ma YY, Yu S, Jiang XT, et al
    Retraction Note: Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho.
    BMC Cancer. 2022;22:766.
    >> Share

  107. YAN Y, Ma Z, Ji X, Liu J, et al
    A potential decision-making algorithm based on endoscopic ultrasound for staging early gastric cancer: a retrospective study.
    BMC Cancer. 2022;22:761.
    >> Share

  108. XU S, Chen W, Wang Y, Zhang Y, et al
    N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
    BMC Cancer. 2022;22:721.
    >> Share

    June 2022
  109. ZHOU M, Yang W, Xuan Y, Zou W, et al
    A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRac
    BMC Cancer. 2022;22:710.
    >> Share

  110. UCARYILMAZ METIN C, Ozcan G
    Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer.
    BMC Cancer. 2022;22:692.
    >> Share

  111. DU Y, Chen Y, Wu T, Fan X, et al
    miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer.
    BMC Cancer. 2022;22:689.
    >> Share

  112. ZHANG X, Wang D, Sun T, Li W, et al
    Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.
    BMC Cancer. 2022;22:684.
    >> Share

  113. VAN SCHOOTEN TS, Derks S, Jimenez-Marti E, Carneiro F, et al
    The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.
    BMC Cancer. 2022;22:646.
    >> Share

  114. MIYATANI K, Sawata S, Makinoya M, Miyauchi W, et al
    Combined analysis of preoperative and postoperative lymphocyte-C-reactive protein ratio precisely predicts outcomes of patients with gastric cancer.
    BMC Cancer. 2022;22:641.
    >> Share

  115. WANG Y, Fang T, Wang Y, Yin X, et al
    Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.
    BMC Cancer. 2022;22:635.
    >> Share

  116. KINOSHITA J, Fushida S, Yamaguchi T, Moriyama H, et al
    Prognostic value of tumor-infiltrating CD163(+)macrophage in patients with metastatic gastric cancer undergoing multidisciplinary treatment.
    BMC Cancer. 2022;22:608.
    >> Share

  117. TSUJIO G, Maruo K, Yamamoto Y, Sera T, et al
    Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.
    BMC Cancer. 2022;22:598.
    >> Share

    May 2022
  118. MATSUNAGA T, Saito H, Osaki T, Takahashi S, et al
    Impact of geriatric nutritional risk index on outcomes after gastrectomy in elderly patients with gastric cancer: a retrospective multicenter study in Japan.
    BMC Cancer. 2022;22:540.
    >> Share

  119. DOS SANTOS M, Lequesne J, Leconte A, Corbinais S, et al
    Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    BMC Cancer. 2022;22:537.
    >> Share

    April 2022
  120. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
    Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
    BMC Cancer. 2022;22:473.
    >> Share

  121. TAN Y, Chen Q, Pan S, An W, et al
    LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway.
    BMC Cancer. 2022;22:474.
    >> Share

  122. CHINEN T, Sasabuchi Y, Matsui H, Yamaguchi H, et al
    Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study.
    BMC Cancer. 2022;22:460.
    >> Share

  123. DALHAMMAR K, Kristensson J, Falkenback D, Rasmussen BH, et al
    Symptoms, problems and quality of life in patients newly diagnosed with oesophageal and gastric cancer - a comparative study of treatment strategy.
    BMC Cancer. 2022;22:434.
    >> Share

  124. LI PC, Huang RY, Yang YC, Hsieh KP, et al
    Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.
    BMC Cancer. 2022;22:430.
    >> Share

  125. SHIN J, Shin DW, Lee J, Hwang J, et al
    Exploring socio-demographic, physical, psychological, and quality of life-related factors related with fear of cancer recurrence in stomach cancer survivors: a cross-sectional study.
    BMC Cancer. 2022;22:414.
    >> Share

  126. MATSUNAGA T, Saito H, Kuroda H, Osaki T, et al
    CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
    BMC Cancer. 2022;22:418.
    >> Share

  127. KIM JH, Ryu MH, Park YS, Ma J, et al
    Predictive biomarkers for the efficacy of nivolumab as >/= 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.
    BMC Cancer. 2022;22:378.
    >> Share

  128. LEI L, Li N, Yuan P, Liu D, et al
    A new risk model based on a 11-m(6)A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer.
    BMC Cancer. 2022;22:365.
    >> Share

    March 2022
  129. WANG Y, Zhu GQ, Tian D, Zhou CW, et al
    Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    BMC Cancer. 2022;22:316.
    >> Share

  130. GOTO K, Morimoto M, Osaki M, Tanio A, et al
    The impact of AMIGO2 on prognosis and hepatic metastasis in gastric cancer patients.
    BMC Cancer. 2022;22:280.
    >> Share

  131. EBERT K, Haffner I, Zwingenberger G, Keller S, et al
    Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
    BMC Cancer. 2022;22:254.
    >> Share

  132. JIANG Z, Zhou A, Sun Y, Zhang W, et al
    Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
    BMC Cancer. 2022;22:253.
    >> Share

  133. CHU XD, Lin ZB, Huang T, Ding H, et al
    Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer.
    BMC Cancer. 2022;22:250.
    >> Share

    February 2022
  134. LI N, Xiang X, Zhao D, Wang X, et al
    Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis.
    BMC Cancer. 2022;22:212.
    >> Share

  135. JIA Z, Zheng M, Jiang J, Cao D, et al
    Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.
    BMC Cancer. 2022;22:155.
    >> Share

  136. BRODSKY AS, Khurana J, Guo KS, Wu EY, et al
    Somatic mutations in collagens are associated with a distinct tumor environment and overall survival in gastric cancer.
    BMC Cancer. 2022;22:139.
    >> Share

    January 2022
  137. LIN L, Li H, Shi D, Liu Z, et al
    Depletion of C12orf48 inhibits gastric cancer growth and metastasis via up-regulating Poly r(C)-Binding Protein (PCBP) 1.
    BMC Cancer. 2022;22:123.
    >> Share

  138. SCHLINTL V, Huemer F, Rinnerthaler G, Melchardt T, et al
    Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
    BMC Cancer. 2022;22:51.
    >> Share

  139. SANO A, Sohda M, Nakazawa N, Ubukata Y, et al
    Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
    BMC Cancer. 2022;22:22.
    >> Share

  140. HENNESSY MA, Hamid M, Keegan NM, Corrigan L, et al
    Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials?
    BMC Cancer. 2022;22:3.
    >> Share

    December 2021
  141. SHI M, Yang Z, Lu S, Liu W, et al
    Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
    BMC Cancer. 2021;21:1344.
    >> Share

  142. CHEN Y, He J, Liu D, Xiao J, et al
    Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
    BMC Cancer. 2021;21:1328.
    >> Share

  143. MA T, Wu Z, Zhang X, Xu H, et al
    Development and validation of a prognostic scoring model for mortality risk stratification in patients with recurrent or metastatic gastric carcinoma.
    BMC Cancer. 2021;21:1326.
    >> Share

  144. ZHANG S, Lv M, Cheng Y, Wang S, et al
    Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
    BMC Cancer. 2021;21:1324.
    >> Share

  145. SAITO H, Shimizu S, Shishido Y, Miyatani K, et al
    Prognostic significance of the combination of preoperative red cell distribution width and platelet distribution width in patients with gastric cancer.
    BMC Cancer. 2021;21:1317.
    >> Share

  146. HAN C, Zhang C, Wang H, Li K, et al
    Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    BMC Cancer. 2021;21:1312.
    >> Share

  147. JIANG L, Zhang Y, Guo L, Liu C, et al
    Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
    BMC Cancer. 2021;21:1290.
    >> Share

  148. XU X, Wang S, Wang H, Pan C, et al
    Hsa_circ_0008434 regulates USP9X expression by sponging miR-6838-5p to promote gastric cancer growth, migration and invasion.
    BMC Cancer. 2021;21:1289.
    >> Share

    November 2021
  149. YANZHANG W, Guanghua L, Zhihao Z, Zhixiong W, et al
    The risk of lymph node metastasis in gastric cancer conforming to indications of endoscopic resection and pylorus-preserving gastrectomy: a single-center retrospective study.
    BMC Cancer. 2021;21:1280.
    >> Share

  150. SUNDE B, Lindblad M, Malmstrom M, Hedberg J, et al
    Health-related quality of life one year after the diagnosis of oesophageal cancer: a population-based study from the Swedish National Registry for Oesophageal and Gastric Cancer.
    BMC Cancer. 2021;21:1277.
    >> Share

  151. KINAMI S, Nakamura N, Miyashita T, Kitakata H, et al
    nPTD classification: an updated classification of gastric cancer location for function preserving gastrectomy based on physiological lymphatic flow.
    BMC Cancer. 2021;21:1231.
    >> Share

  152. MATSUNAGA T, Saito H, Miyauchi W, Shishido Y, et al
    Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
    BMC Cancer. 2021;21:1219.
    >> Share

  153. WEI J, Zeng Y, Gao X, Liu T, et al
    A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer.
    BMC Cancer. 2021;21:1221.
    >> Share

  154. WU WW, Zhang WH, Zhang WY, Liu K, et al
    The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study.
    BMC Cancer. 2021;21:1193.
    >> Share

  155. CHEN S, Lai H, Zhao J, Chen B, et al
    The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy.
    BMC Cancer. 2021;21:1183.
    >> Share

    October 2021
  156. LIU R, Yang X
    LncRNA LINC00342 promotes gastric cancer progression by targeting the miR-545-5p/CNPY2 axis.
    BMC Cancer. 2021;21:1163.
    >> Share

  157. GOTZE TO, Piso P, Lorenzen S, Bankstahl US, et al
    Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
    BMC Cancer. 2021;21:1158.
    >> Share

  158. WANG Q, Zhong J, Huang Q, Chen Z, et al
    A survival comparison of gastric mucin-producing adenocarcinoma to conventional adenocarcinoma: a SEER database analysis.
    BMC Cancer. 2021;21:1138.
    >> Share

  159. GIOMMONI E, Lavacchi D, Tirino G, Fornaro L, et al
    Results of the observational prospective RealFLOT study.
    BMC Cancer. 2021;21:1086.
    >> Share

  160. HIRAHARA N, Matsubara T, Kaji S, Yamamoto T, et al
    Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    BMC Cancer. 2021;21:1073.
    >> Share

    September 2021
  161. JIANG Q, Chen H, Tang Z, Sun J, et al
    Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer.
    BMC Cancer. 2021;21:1067.
    >> Share

  162. YURA M, Yoshikawa T, Wada T, Otsuki S, et al
    The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer.
    BMC Cancer. 2021;21:1056.
    >> Share

  163. LIU S, Xu M, Qiao X, Ji C, et al
    Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images.
    BMC Cancer. 2021;21:1038.
    >> Share

  164. CORDOVA-DELGADO M, Bravo ML, Cumsille E, Hill CN, et al
    A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    BMC Cancer. 2021;21:1030.
    >> Share

  165. PARK SH, Suh YS, Kim TH, Choi YH, et al
    Postoperative morbidity and quality of life between totally laparoscopic total gastrectomy and laparoscopy-assisted total gastrectomy: a propensity-score matched analysis.
    BMC Cancer. 2021;21:1016.
    >> Share

    August 2021
  166. CHEN L, Zhang C, Yao Z, Cui M, et al
    Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
    BMC Cancer. 2021;21:974.
    >> Share

  167. LI HQ, Xue H, Yuan H, Wan GY, et al
    Preferences of first-degree relatives of gastric cancer patients for gastric cancer screening: a discrete choice experiment.
    BMC Cancer. 2021;21:959.
    >> Share

  168. UOZUMI T, Sumiyoshi T, Tomita Y, Tokuchi K, et al
    Does second-look endoscopy reduce the bleeding after gastric endoscopic submucosal dissection for patients receiving antithrombotic therapy?
    BMC Cancer. 2021;21:946.
    >> Share

  169. NING G, Zhu Q, Kang W, Lee H, et al
    A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
    BMC Cancer. 2021;21:923.
    >> Share

  170. WANG J, Xu P, Hao Y, Yu T, et al
    Interaction between DNMT3B and MYH11 via hypermethylation regulates gastric cancer progression.
    BMC Cancer. 2021;21:914.
    >> Share

    July 2021
  171. YEN CC, Shan YS, Chao YJ, Liao TK, et al
    Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
    BMC Cancer. 2021;21:796.
    >> Share

  172. ZHOU YJ, Lu XF, Meng JL, Wang XY, et al
    Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
    BMC Cancer. 2021;21:771.
    >> Share

    June 2021
  173. SANTERO M, Perez-Bracchiglione J, Acosta-Dighero R, Meade AG, et al
    Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews.
    BMC Cancer. 2021;21:712.
    >> Share

  174. YE Z, Zeng Y, Wei S, Wang Y, et al
    Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
    BMC Cancer. 2021;21:702.
    >> Share

  175. LU XQ, Zhang JQ, Zhang SX, Qiao J, et al
    Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.
    BMC Cancer. 2021;21:697.
    >> Share

  176. WU R, Guo S, Lai S, Pan G, et al
    A stable gene set for prediction of prognosis and efficacy of chemotherapy in gastric cancer.
    BMC Cancer. 2021;21:684.
    >> Share

  177. ZHANG J, Lv W, Liu Y, Fu W, et al
    LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p.
    BMC Cancer. 2021;21:657.
    >> Share

    May 2021
  178. DAI J, Nishi A, Li ZX, Zhang Y, et al
    DNA methylation signatures associated with prognosis of gastric cancer.
    BMC Cancer. 2021;21:610.
    >> Share

  179. RUSTGI SD, Oh A, Yang JY, Kang D, et al
    Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
    BMC Cancer. 2021;21:597.
    >> Share

  180. CHEN Y, Hu N, Liao L, Yu K, et al
    ABO genotypes and the risk of esophageal and gastric cancers.
    BMC Cancer. 2021;21:589.
    >> Share

  181. O'CONNOR L, Smyth E, Bennett AE, Smith V, et al
    Identifying outcomes reported in exercise interventions in oesophagogastric cancer survivors: a systematic review.
    BMC Cancer. 2021;21:586.
    >> Share

  182. CHUN SH, Kim EY, Yoon JS, Won HS, et al
    Prognostic value of noggin protein expression in patients with resected gastric cancer.
    BMC Cancer. 2021;21:558.
    >> Share

  183. NIE C, Han X, Wei R, Leonteva A, et al
    Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
    BMC Cancer. 2021;21:551.
    >> Share

  184. CHEN J, Xia YJ, Liu TY, Lai YH, et al
    Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data.
    BMC Cancer. 2021;21:532.
    >> Share

    April 2021
  185. LIU N, Wu Y, Cheng W, Wu Y, et al
    Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer.
    BMC Cancer. 2021;21:460.
    >> Share

  186. ZHONG X, Xuan F, Qian Y, Pan J, et al
    A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer.
    BMC Cancer. 2021;21:455.
    >> Share

  187. LIU L, Zhang C, Wang J, Liu X, et al
    A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer.
    BMC Cancer. 2021;21:453.
    >> Share

  188. YU J, Jung J, Park SR, Ryu MH, et al
    Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer.
    BMC Cancer. 2021;21:413.
    >> Share

  189. YU Y, Xie Z, Zhao M, Lian X, et al
    Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer.
    BMC Cancer. 2021;21:368.
    >> Share

    March 2021
  190. KIM TH, Do Cho H, Choi YW, Lee HW, et al
    Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data.
    BMC Cancer. 2021;21:325.
    >> Share

  191. CAI Z, Song H, Fingerhut A, Sun J, et al
    A greater lymph node yield is required during pathological examination in microsatellite instability-high gastric cancer.
    BMC Cancer. 2021;21:319.
    >> Share

  192. LIANG Y, Zhao L, Chen H, Lin T, et al
    Correction to: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
    BMC Cancer. 2021;21:298.
    >> Share

  193. JI J, Chen J, Wang A, Zhang W, et al
    KK-LC-1 may be an effective prognostic biomarker for gastric cancer.
    BMC Cancer. 2021;21:267.
    >> Share

  194. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    >> Share

  195. HE P, Cheng S, Hu F, Ma Z, et al
    Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
    BMC Cancer. 2021;21:252.
    >> Share

  196. GE Y, Wei F, Du G, Fei G, et al
    The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    BMC Cancer. 2021;21:240.
    >> Share

  197. OKAGAWA Y, Sumiyoshi T, Kondo H, Tomita Y, et al
    Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer.
    BMC Cancer. 2021;21:235.
    >> Share

  198. EHARA T, Uehara T, Nakajima T, Kinugawa Y, et al
    LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma.
    BMC Cancer. 2021;21:228.
    >> Share

  199. FAN B, Bu Z, Zhang J, Zong X, et al
    Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery.
    BMC Cancer. 2021;21:216.
    >> Share

  200. LIM JH, Song JH, Chung SJ, Chung GE, et al
    Characteristics of interval gastric neoplasms detected within two years after negative screening endoscopy among Koreans.
    BMC Cancer. 2021;21:218.
    >> Share

    February 2021
  201. LIANG Y, Zhao L, Chen H, Lin T, et al
    Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
    BMC Cancer. 2021;21:196.
    >> Share

  202. CHEN XJ, Chen GM, Wei YC, Yu H, et al
    Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis.
    BMC Cancer. 2021;21:188.
    >> Share

  203. KIM KW, Lee K, Lee JB, Park T, et al
    Preoperative nutritional risk index and postoperative one-year skeletal muscle loss can predict the prognosis of patients with gastric adenocarcinoma: a registry-based study.
    BMC Cancer. 2021;21:157.
    >> Share

  204. BAEG K, Harris C, Naparst MS, Ahn E, et al
    Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    BMC Cancer. 2021;21:146.
    >> Share

    January 2021
  205. ITO A, Kagawa S, Sakamoto S, Kuwada K, et al
    Extracellular vesicles shed from gastric cancer mediate protumor macrophage differentiation.
    BMC Cancer. 2021;21:102.
    >> Share

  206. OKUBO K, Arigami T, Matsushita D, Kijima T, et al
    Clinical impact of creatine phosphokinase and c-reactive protein as predictors of postgastrectomy complications in patients with gastric cancer.
    BMC Cancer. 2021;21:95.
    >> Share

  207. EMBAYE KS, Zhang C, Ghebrehiwet MA, Wang Z, et al
    Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia.
    BMC Cancer. 2021;21:92.
    >> Share

  208. CHENG X, Wu D, Xu N, Chen L, et al
    Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    BMC Cancer. 2021;21:56.
    >> Share

  209. TONG Y, Zhao Y, Shan Z, Zhang J, et al
    CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:4.
    >> Share

  210. TAO S, Gu J, Wang Q, Zheng L, et al
    Translational control of Bcl-2 promotes apoptosis of gastric carcinoma cells.
    BMC Cancer. 2021;21:12.
    >> Share

  211. WANG X, Li S, Sun Y, Li K, et al
    The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
    BMC Cancer. 2021;21:20.
    >> Share

  212. SMITH-PALMER J, Leeuwenkamp OR, Virk J, Reed N, et al
    Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland.
    BMC Cancer. 2021;21:10.
    >> Share

    November 2020
  213. EBERT K, Zwingenberger G, Barbaria E, Keller S, et al
    Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
    BMC Cancer. 2020;20:1127.
    >> Share

  214. YU P, Ye Z, Dai G, Zhang Y, et al
    Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
    BMC Cancer. 2020;20:1108.
    >> Share

  215. WU R, Yang C, Ji L, Fan ZN, et al
    Prevalence of gastric cancer precursors in gastroscopy-screened adults by family history of gastric cancer and of cancers other than gastric.
    BMC Cancer. 2020;20:1110.
    >> Share

  216. OKUNAKA M, Kotani D, Demachi K, Kawazoe A, et al
    Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    BMC Cancer. 2020;20:1111.
    >> Share

  217. MASUI T, Ito T, Komoto I, Uemoto S, et al
    Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    BMC Cancer. 2020;20:1104.
    >> Share

    October 2020
  218. EBERT K, Zwingenberger G, Barbaria E, Keller S, et al
    Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
    BMC Cancer. 2020;20:1039.
    >> Share

  219. FUJIMORI D, Kinoshita J, Yamaguchi T, Nakamura Y, et al
    Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer.
    BMC Cancer. 2020;20:1014.
    >> Share

  220. WANG JB, Xue Z, Lu J, He QL, et al
    Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series.
    BMC Cancer. 2020;20:1002.
    >> Share

  221. XUE X, Huang J, Yu K, Chen X, et al
    YB-1 transferred by gastric cancer exosomes promotes angiogenesis via enhancing the expression of angiogenic factors in vascular endothelial cells.
    BMC Cancer. 2020;20:996.
    >> Share

    September 2020
  222. SONKAR C, Verma T, Chatterji D, Jain AK, et al
    Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells.
    BMC Cancer. 2020;20:925.
    >> Share

  223. LORENZEN S, Biederstadt A, Ronellenfitsch U, Reissfelder C, et al
    RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    BMC Cancer. 2020;20:886.
    >> Share

  224. YOON JY, Brezden-Masley C, Streutker CJ
    Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.
    BMC Cancer. 2020;20:860.
    >> Share

    August 2020
  225. LEERS JM, Knepper L, van der Veen A, Schroder W, et al
    The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II.
    BMC Cancer. 2020;20:781.
    >> Share

  226. CHEN J, Wang A, Ji K, Bu Z, et al
    Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study.
    BMC Cancer. 2020;20:777.
    >> Share

  227. JIANG H, Zheng Y, Qian J, Mao C, et al
    Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    BMC Cancer. 2020;20:760.
    >> Share

  228. SHADMANI FK, Farzadfar F, Yoosefi M, Mansori K, et al
    Premature mortality of gastrointestinal cancer in Iran: trends and projections 2001-2030.
    BMC Cancer. 2020;20:752.
    >> Share

    July 2020
  229. ZHOU K, Wang A, Ao S, Chen J, et al
    The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis.
    BMC Cancer. 2020;20:671.
    >> Share

  230. LIN JL, Lin JX, Zheng CH, Li P, et al
    Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
    BMC Cancer. 2020;20:638.
    >> Share

    June 2020
  231. REHKAEMPER J, Korenkov M, Quaas A, Rueschoff J, et al
    Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas.
    BMC Cancer. 2020;20:587.
    >> Share

  232. RICHARDS HS, Blazeby JM, Portal A, Harding R, et al
    A real-time electronic symptom monitoring system for patients after discharge following surgery: a pilot study in cancer-related surgery.
    BMC Cancer. 2020;20:543.
    >> Share

  233. GU E, Song W, Liu A, Wang H, et al
    SCDb: an integrated database of stomach cancer.
    BMC Cancer. 2020;20:490.
    >> Share

  234. TINTELNOT J, Goekkurt E, Binder M, Thuss-Patience P, et al
    Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    BMC Cancer. 2020;20:503.
    >> Share

    May 2020
  235. O'NEILL L, Guinan E, Doyle S, Connolly D, et al
    Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial.
    BMC Cancer. 2020;20:415.
    >> Share

    April 2020
  236. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016